1. A method for preventing fibrotic lung disease in a subject, wherein the method comprises administering to the subject an inhibitor of the activity of a lysyl oxidase-like protein 2 (LOXL2). The method of claim 1, wherein the pulmonary fibrotic disease is selected from the group consisting of intercitial pneumonia, acute respiratory distress syndrome (ARDS), and idiopathic fibrotic pulmonary disease (IPF). The method of claim 1, wherein the inhibitor is an anti-LOXL2.4 antibody. The method of claim 3, wherein the antibody comprises the heavy chain sequences presented in SEQ ID NO: 1 and the light chain sequences presented in SEQ ID NO: 2.5. The method of claim 3, wherein the antibody is a humanized antibody. The method of claim 5, wherein the antibody comprises the heavy chain sequences presented in SEQ ID NO: 3 and the light chain sequences presented in SEQ ID NO: 4.7. A method for treating fibrotic lung disease in a subject, the method comprising administering to a patient an inhibitor of the activity of a lysyl oxidase-like protein 2 (LOXL2) .8. The method of claim 7, wherein the pulmonary fibrotic disease is selected from the group consisting of intercitial pneumonia, acute respiratory distress syndrome (ARDS), and idiopathic pulmonary fibrosis (IPF). The method of claim 7, wherein the inhibitor is an anti-LOXL2.10 antibody. The method of claim 9, wherein the antibody comprises the heavy chain sequences presented in SEQ ID NO: 1 and the light chain sequences presented in SEQ ID NO: 2.11. The method of claim 9, wherein the antibody is a humanized antibody. The method of claim 11, wherein the antibody comprises the heavy chain sequences shown in SEQ ID NO: 3 and the light chain sequences1. Способ предотвращения фиброзного заболевания легких у субъекта, где способ включает введение субъекту ингибитора активности лизилоксидазоподобного белка 2 (LOXL2).2. Способ по п. 1, в котором фиброзное заболевание легких выбирают из группы, состоящей из интерсцитиальной пневмо
